TC
BMRN icon

Trust Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Trust Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$60 Hold
1
– – ﹤0.01% 905
2026
Q2 		$57 Hold
1
– – ﹤0.01% 899
2026
Q1 		$56 Hold
1
– – ﹤0.01% 894
2025
Q4 		$59 Buy
+1
New +$54 ﹤0.01% 878

Other funds holding BMRN

FFBTD
First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Trust Company's BMRN Position: Q3 2026 in Review

Trust Company held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 1 share worth $60. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Trust Company first reported a position in BMRN in Q4 2025 and has held it in 4 quarters since. 17 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Trust Company held 1 share of BioMarin Pharmaceuticals worth $60 as of Q3 2026.
  • Trust Company left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Trust Company's portfolio in Q3 2026, its #905 holding.
  • Trust Company first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 17 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Trust Company's 13F filing for Q3 2026, filed 9 Oct 2026.